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Abstract
Background: The combination of oleoyl-estrone (OE) and a selective b3-adrenergic agonist (B3A; CL316,243)
treatment in rats results in a profound and rapid wasting of body reserves (lipid).
Methods: In the present study we investigated the effect of OE (oral gavage) and/or B3A (subcutaneous constant
infusion) administration for 10 days to overweight male rats, compared with controls, on three distinct white
adipose tissue (WAT) sites: subcutaneous inguinal, retroperitoneal and epididymal. Tissue weight, DNA (and, from
these values cellularity), cAMP content and the expression of several key energy handling metabolism and control
genes were analyzed and computed in relation to the whole site mass.
Results: Both OE and B3A significantly decreased WAT mass, with no loss of DNA (cell numbers). OE decreased
and B3A increased cAMP. Gene expression patterns were markedly different for OE and B3A. OE tended to
decrease expression of most genes studied, with no changes (versus controls) of lipolytic but decrease of lipogenic
enzyme genes. The effects of B3A were widely different, with a generalized increase in the expression of most
genes, including the adrenergic receptors, and, especially the uncoupling protein UCP1.
Discussion: OE and B3A, elicit widely different responses in WAT gene expression, end producing similar effects,
such as shrinking of WAT, loss of fat, maintenance of cell numbers. OE acted essentially on the balance of lipolysis-
lipogenesis and the blocking of the uptake of substrates; its decrease of synthesis favouring lipolysis. B3A induced
a shotgun increase in the expression of most regulatory systems in the adipocyte, an effect that in the end
favoured again the loss of lipid; this barely selective increase probably produces inefficiency, which coupled with
the increase in UCP1 expression may help WAT to waste energy through thermogenesis.
Conclusions: There were considerable differences in the responses of the three WAT sites. OE in general lowered
gene expression and stealthily induced a substrate imbalance. B3A increasing the expression of most genes
enhanced energy waste through inefficiency rather than through specific pathway activation. There was not a
synergistic effect between OE and B3A in WAT, but their combined action increased WAT energy waste.
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White adipose tissue (WAT) is a fairly active agent in
the regulation of the energy availability of the body [1],
superseding its classic role of energy storage depot [2]
and playing a role in the endocrine/paracrine and meta-
bolic regulation of energy substrate utilization [3]. The
main elements that WAT employs in this regulative role
are: a) its large capability to store energy as triacylgly-
cerols, depleting circulating levels [4], a function that
extends in part to the removal of excess glucose [5]
used for lipogenesis [6]; b) its ability to reverse the sto-
rage process, releasing fatty acids to the bloodstream
through lipolysis [7]; c) the modulation of other (and
self) tissues through the secretion of hormones and
paracrine agents [8]; and d) the wasting of energy, a
postulated role [9] traditionally attributed to brown adi-
pose tissue, and insufficiently characterized in WAT.
Oleoyl-estrone (OE) is a signalling molecule from
WAT that has been postulated as a ponderostat modify-
ing agent [10], since its administration induces a severe
wasting of the body fat reserves [11], reducing WAT
lipogenesis and substrate uptake rather than elicit
increases in lipolysis, increasing fatty acid output [12].
This process is in part mediated, at least in liver, by
SREBP1c [13], under conditions in which glycolysis is
not completely blocked irrespective of a large availability
of fatty acids [14]. Notwithstanding, basically the OE
mechanism of action remains largely unknown.
The combined administration of a specific b3-adrener-
gic agonist with OE results ina na s s u m e d l ys y n e r g i s t i c
effect of both agents inducing a massive WAT wasting,
but nevertheless maintaining the circulating levels of the
main metabolic indicators within the normalcy range
[15]. OE reduces WAT mass at the expense of a
decrease in energy intake with maintained thermogen-
esis [16,17], whilst most b3-adrenergic agonists elicit a
massive lipolysis to fuel an increased thermogenesis, but
barely affect food intake [18], and tend to show limited
effects because of downregulation of the receptors [19].
The discovery of b3-adrenergic receptors in brown and
white adipose tissue [20] generated an enormous
research effort to obtain agonists for these receptors
that could elicit an increase in thermogenesis without
the dangerous secondary effects of unspecific b-adrener-
gic stimulation [21,22]. A large number of compounds
were obtained [22] but none was finally commercialized
because of the short-time span of their efficacy and the
rapid down-regulation of the receptors [20]. There is a
number of b3-adrenergic agonists available that show
very little superposition in their effects with b1 or b2
receptors. We had previously used CL316,243 [15] in a
previous gross-energy study, in combination of OE, and
found that this combination deeply affected the body
energy reserves [15]. As a continuation, the purpose of
this study is to check how WAT responds to the double
challenge, determining whether there is a common shar-
ing of pathways for WAT energy disposal, or their
actions upon the tissue follow separate strategies.
Finally, we also wanted to know whether there is (or
not) a synergistic effect favoring the depletion of body
fat when using the combined slimming agents approach.
Methods
Animals and experimental setup
Male Wistar rats (Harlan-Interfauna, Sant Feliu de
Codines, Spain) of 45 days were used. The rats were
maintained under standard conditions (21-22°C, 60-50
% relative humidity, and 12 h light/dark cycle: on from
08.00) in three-rat cages, and were fed for five weeks a
simplified cafeteria diet [20]ad libitum.A sp r e v i o u s l y
described [23], at the end of this phase the rats were
already overweight; the animals were re-conditioned to
eat standard pellet diet as sole food during an additional
week (maintenance chow, Panlab, Barcelona, Spain).
Four groups of six animals, initially weighing 360-380
g, were randomly selected: a) Controls; b) oleoyl-estrone:
OE; c) b3-adrenergic agonist (B3A) CL316,243: B3A; and
d) oleoyl-estrone and b3-adrenergic agonist: OE+B3A.
Groups B3A and OE+B3A were implanted on day 0
subcutaneously in the back with an osmotic Alzet minu-
pump (type 2002, Alzet, Palo Alto CA, USA) under iso-
flurane anaesthesia; the minipumps were loaded with
B3A, the b3-adrenergic agonist CL316,243 [24](Sigma,
St Louis, MO USA) dissolved in saline. The minipumps
released B3A at a rate of 0.5 μl/h in the subcutaneous
space, at a dose of 1 mg/kg and day. The rats in the OE
and OE+B3A groups received a gavage containing OE
(OED, Barcelona, Spain) in 0.2 ml sunflower oil, at a
daily dose of 10 μmol/kg. The gavage of rats in the con-
trol and B3A groups contained only oil. The rats were
given the gavages at the beginning of the light cycle,
and were maintained under standard housing condi-
tions, with full access to water and food pellets; their
weight and food consumption were recorded daily. The
treatments continued for 10 days.
At the end of the experiment, the rats were killed by
decapitation. The rats were dissected and samples of
inguinal, retroperitoneal and epididymal WAT were
rapidly taken, frozen in liquid N and weighed. Then, the
three WAT pads (inguinal subcutaneous, retroperitoneal
and epididymal) were completely dissected, blotted and
weighed in order to obtain the total mass of each WAT
site. Tissue samples were maintained at -80°C until used
The experimental setup and procedures were
approved by the Ethics Committee of the University of
Barcelona. All animal handling procedures were carried
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the Spanish and Catalan Governments.
Nucleic acid analyses, cellularity
Tissue samples were used for the estimation of total
DNA, using a standard fluorimetric method with 3,5-
diaminobenzoic acid (Sigma, St Louis MO USA) and
bovine DNA (Sigma) as standard [25]. Tissue DNA con-
tent allowed the calculation of the number of cells per g
of tissue and in the whole tissues sampled, based on the
assumption that the DNA content per cell is constant in
mammals; here we used the genomic DNA size data
[26] for somatic rat cells (5.6 pg/cell). Mean cell mass
was estimated from the number of cells and the tissue
weight.
Total tissue RNA was extracted using the Tripure
reagent (Roche Applied Science, Indianapolis IN USA),
and were quantified in a ND-100 spectrophotometer
(Nanodrop Technologies, Wilmington DE USA).
Semiquantitative RT-PCR analysis of gene expression
RNA samples were reverse transcribed using the MMLV
reverse transcriptase (Promega, Madison, W I USA) and
oligo-dT primers. Real-time PCR (RT-PCR) amplifica-
tion was carried out using 0.010 mL amplification mix-
tures containing Power SYBR Green PCR Master Mix
(Applied Biosystems, Foster City, CA USA), equivalent
to 8 ng of reverse-transcribed RNA and 300 nM
primers. Reactions were run on an ABI PRISM 7900
HT detection system (Applied Biosystems) using a fluor-
escent threshold manually set to OD 0.500 for all runs.
W e analyzed the expression of the genes listed in the
Additional File 1 Table S1, which includes the list of
primers used.
A semiquantitative approach for the ultimate estima-
tion of the number of copies of each expressed gene
mRNAs per tissue weight was used as previously
described [27]. ARBP was used as charge control gene
in all samples. All primers were selected and optimized
to obtain values of r ≥ 0.98, resulting in an efficiency
range of 93-104 %.
cAMP analysis
Frozen tissue samples were homogenized in chilled per-
chloric acid 30 g/L [28] using a Polytron tissue disruptor
(ultraturrax, Kinematica, Luzern, Switzerland); after neu-
tralization with 2N NaOH, supernatants were used for a
cAMP binding assay using a specific kit (TRK432, GE
Healthcare, Little Chalfont, UK). Results for cAMP were
expressed in amol/cell; cAMP data, as well as specific
gene mRNA content in the tissue were expressed as
absolute data of content in the whole of the specific fat
pad, as a way to specifically discriminate the global
WAT site response to the stimuli regardless of cell size
or number, parameters that may be also influenced by
the treatments [16,27].
Statistical analysis
In addition to the three sites studied, a fourth group of
data was included, corresponding to the sum of the
three sites. The data were obtained tabulating the
experimental results for each animal. Statistical two-way
ANOVA analyses was carried out using the Prism 5
program package (GraphPad Software, La Jolla, CA
USA), with a limit of significance of P < 0.05. Spot com-
parisons between groups were done using the unpaired
Student’s t test.
Results
Body weight, tissue cellularity and cAMP levels
Figure 1 shows the changes in body weight and food
intake elicited by the 10-day pharmacologic treatment.
Control rats increased their weight by a 2.4 ± 0.7 %; OE
rats lost 13.7 ± 1.4 %, B3A lost 2.2 ± 2.5 % and OE+B3A
lost 11.7 ± 1.0 % in 10 days; the effect of OE was
s i g n i f i c a n t( P<0 . 0 0 0 1 )b u tn o tt h a to fB 3 A ;t h e r ew a sa
significant (P = 0.0468) interaction between both agents
(two-way ANOVA). Food intake in controls was a mean
18.6 ± 0.8 g/day, in the B3A group it was slightly
decreased (16.3 ± 1.1 g/day), and showed even lower
values in the OE (8.4 ± 0.6 g/day) and combined OE+B3A
( 1 2 . 8±0 . 9g / d )g r o u p s ;t h ee f f e c t so fO Eo nf o o di n t a k e
were statistically significant (P < 0.0001), but not those of
B3A (two-way ANOVA).
Table 1 presents the data on total weight and cellular-
ity of the three WAT sites studied. Both agents induced
marked reductions in weight, with significant effects of
both OE and B3A. These effects were extended to the
sum of the weight of these WAT sites, resulting in over-
all losses in the range of 60 % in the combined WAT
mass for the OE+B3A group.
The estimated number of cells was not affected in any
of the three WAT sites by either treatment; however,
the mean cell weight decreased in all (as did their over-
all mass), the effects of B3A being significant for all sites
and those of OE for none of them.
Table 2 shows the cAMP content of WAT after treat-
ment with OE and B3A. OE effects were limited: the
only significant values were decreases in epididymal
WAT (only when expressed per cell unit), and in the
total content of retroperitoneal and combined WAT. In
contrast, B3A increased the cAMP levels of epididymal
and combined WAT sites. No significant interactions
were observed.
Tissue gene expressions in individual WAT sites
T h et i s s u el e v e l so fs p e c i f i cm R N A sf o rt h eg e n e ss t u -
died are presented in the Additional File 1, Tables S2,
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mal, retroperitoneal and combined WAT sites. The sta-
tistical analysis of the differences in expression of the
genes for these WAT sites is presented in Figure 2.
In subcutaneous WAT, OE decreased the expression of
b1 and b2-adrenoceptor genes, as well as PPAR-a and
PPAR-b/δ. Insulin signaling was decreased: lower expres-
sions of insulin receptor (but also its degrading enzyme),
IRS-1, and GLUT-4 genes. A similar decrease in
expression was observed for lipogenic agents SRBP1c,
and acetyl-CoA carboxylase genes. Lipoprotein lipase,
UCP3 and the cytokines leptin, resistin and visfatin
expressions were also decreased. The effects of B3A were
markedly different, since in this case all gene expressions
studied were increased with respect to controls, with the
(non statistically significant) exceptions of the b1-adrenal
receptor, PPAR-b/δ, fatty acid synthase, adiponutrin,
UCP1, UCP2, and the cytokines leptin and TNFa.
Figure 1 Body weight and food intake changes in overweight rats treated with OE and/or B3A during the 10-day study. The data are
the mean ± sem of six different animals.
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OE was less marked in epididymal than in subcutaneous
WAT, with only significant changes in PPARg1,G L U T
4, lipoprotein lipase, adiponutrin, UCP3, leptin and
resistin genes. However, the increases in gene expression
induced by B3A were fully comparable to those of sub-
cutaneous WAT, the only differences being: no signifi-
cant effects on b-adrenal receptors, IRS-1, UCP3 and
adiponectin genes, but significant differences in fatty
acid synthase and UCP1 gene expressions.
In retroperitoneal WAT, OE effects on gene expres-
sion were again different from the other two WAT sites.
OE induced significant decreases in the gene expression
of PPAR-a, GLUT4 and a number of lipid-metabolism
related genes: SREBP1c, acetyl-CoA carboxylase 1, fatty
acid synthase, lipoprotein lipase and adiponutrin. OE
also induced decreases in the expression of UCP2 and
the adipokines TNFa, leptin and resistin. The adminis-
tration of B3A (alone or combined with OE) induced
much less change in gene. expressions than in subcuta-
neous and retroperitoneal WAT. In this case B3A
induced a decrease in the expression of the visfatin gene
and increases in the b3-adrenergic receptor,
phosphodiesterase 3B, PPAR-a, acetyl-CoA carboxylase,
carnitine palmitoleoyl-transferase, fatty acid transporting
protein 1, the UCPs, TNFa, leptin and resistin.
Tissue gene expressions in combined WAT
When the data for gene specific transcripts present in
the combined WAT sites were analyzed, the results
became perhaps more clear: OE induced decreases in
the expression of most genes studied, with the excep-
tions of b3-adrenergic receptor and phosphodiesterase
3B, PPARg2, and IRS-1 as critical signaling and signal-
transduction agents. There is a second group in which
OE overall did not change significantly the expression of
the WAT genes, all related with lipolysis and fatty acid
import/transport: hormone sensitive lipase, adipocyte
TAG lipase, carnitine palmitoleoyl-transferase, and the
fatty acid binding and transporting protein genes, as
well as the markedly apoptotic-inducing adipokine
TNF-a gene; these genes maintained mRNA strengths
comparable with those of controls despite WAT size
reduction, since they showed no significant differences
in absolute terms. The effects of B3A were markedly
uniform: all genes studied increased their expression
Table 1 Weight/cell content of three main WAT sites of overweight male rats treated for 10 days with combined OE
and B3A
parameter units control OE B3A OE+B3A P- OE P-B3A P-int
inguinal subcutaneous WAT weight g 4.30 ± 0.28 3.49 ± 0.31 3.04 ± 0.56 2.87 ± 0.54 NS 0.0339 NS
epidydimal WAT weight g 10.37 ± 0.92 8.59 ± 0.53 6.47 ± 0.61 5.05 ± 0.90 0.0481 0.0000 NS
retroperitoneal WAT weight g 11.81 ± 1.24 8.19 ± 0.69 3.20 ± 0.64 3.26 ± 0.64 0.0408 0.0000 0.0472
combined WAT weight g 26.48 ± 3.07 20.27 ± 1.31 12.71 ± 1.75 10.53 ± 1.39 0.0497 0.0000 NS
inguinal subcutaneous WAT cellularity 10
6 cells 618 ± 74 549 ± 55 549 ± 29 553 ± 53 NS NS NS
inguinal subcutaneous WAT cell mass ng 7.66 ± 1.24 6.83 ± 0.71 6.21 ± 0.45 4.24 ± 0.61 NS 0.0213 NS
epidydimal WAT cellularity 10
6 cells 359 ± 45 439 ± 32 459 ± 75 385 ± 16 NS NS 0.0039
epidydimal WAT cell mass ng 24.9 ± 1.3 22.4 ± 1.9 12.9 ± 1.1 12.5 ± 0.8 NS 0.0000 NS
retroperitoneal WAT cellularity 10
6 cells 431 ± 70 340 ± 69 372 ± 11 377 ± 73 NS NS NS
retroperitoneal WAT cell mass ng 28.1 ± 1.8 29.0 ± 6.0 7.54 ± 0.33 8.29 ± 0.90 NS 0.0000 NS
The values are the mean ± sem of 6 different animals. Statistical significance of the diferences (2-way ANOVA): P-OE/PB3A represents the P values for OE/B3A
inducing a significant effect on the given parameter; P-int indicates the significance of the interaction between both agonists. NS = p > 0.05.
Table 2 cAMP tissue/cell content in three main WAT sites of overweight male rats treated for 10 days with combined
OE and B3A
organ/tissue units control OE B3A OE+B3A P-OE P-B3A P-int
inguinal subcutaneous WAT amol/cell 1.91 ± 0.42 1.92 ± 0.30 2.37 ± 0.37 1.88 ± 0.59 NS NS NS
nmol 0.93 ± 0.11 0.73 ± 0.09 1.14 ± 0.22 0.97 ± 0.22 NS NS NS
epididymal WAT amol/cell 3.74 ± 0.57 2.72 ± 0.20 5.92 ± 0.39 4.71 ± 0.36 0.0117 0.0000 NS
nmol 1.35 ± 0.17 1.09 ± 0.10 2.61 ± 0.31 2.06 ± 0.31 NS 0.0002 NS
retroperitoneal WAT amol/cell 6.02 ± 0.42 4.53 ± 0.86 4.64 ± 0.20 3.83 ± 0.75 NS NS NS
nmol 2.52 ± 0.30 1.31 ± 0.26 1.75 ± 0.23 1.61 ± 0.27 0.0197 NS NS
combined WAT nmol 4.79 ± 0.43 3.49 ± 0.35 5.49 ± 0.46 4.66 ± 0.67 0.0427 0.0000 NS
The values are the mean ± sem of 6 different animals. Statistical significance of the diferences (2-way ANOVA): P-OE/PB3A represents the P values for OE/B3A
inducing a significant effect on the given parameter; P-int indicates the significance of the interaction between both agonists. NS = p > 0.05.
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b2-adrenal receptors and leptin.
Discussion
OE effects on the overall energy economy [11,16] are
often more marked than in the actual changes in plasma
metabolite [11,29] levels or the spectrum of gene
expression changes [12-14]. This includes WAT, which
in the end provides most of the energy wasted to main-
tain energy expenditure under a decreased energy intake
also consequence of OE treatment [30]. In the present
s t u d yw eh a v ec o n f i r m e dt h ec o n s i d e r a b l ed i f f e r e n c e s
that the main WAT sites present with respect to their
response to OE [31] or to other hormonal [32] or phar-
macological agents [33].
It has been postulated that OE decreases WAT energy
content by deregulating the equilibrium between lipo-
genesis (and triacylglycerol synthesis) and lipolysis
[12,13]. In spite of marked differences between WAT
sites, the cells of rats treated with OE were shrunk by
the loss of fat; their decreased cAMP levels agreed with
a generalized depression of lipogenesis. The lipolytic
paths were not (or less-) affected, and fatty acid trans-
port (both in, out of the cell, as well as into the
Figure 2 P values for the statistical significance of the effects of OE and B3A on the gene expression of lipid metabolism -related
enzymes and factors in the main sites of WAT of male overweight rats treated with OE and a B3A (two-way ANOVA). Data in bold red
italics represent significant decreases in the combined specific mRNA content in the given WAT site (and, in the case of “combined WAT” in the
sum of all three sites) compared with controls receiving vehicle only. Data in bold green represent significant increases. Non-significant effects
(NS) are in black. An asterisk * in the interaction (int) column denotes a significant (P < 0.05) interaction between OE and B3A effects.
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previously (and the present result confirm -at least for
WAT-) that OE does not induce marked changes in the
expression of adrenergic receptor genes [28].
OE seems to induce a lethargic metabolic transforma-
tion of WAT, with generalized inhibition of metabolic
activity, loss of fat and decrease in overall size [12]
diminished hormonal and cytokine [31] signaling, and a
more marked inhibition of the entry of energy sub-
strates. Nevertheless, OE induces a marked loss of fat
maintaining thermogenesis and the energy homeostasis
exemplified by metabolite levels in plasma [29].
The b3-adrenergic agonists were initially designed as
brown adipose tissue stimulators -i.e. thermogenic
agents- [34] because of their abundance in this tissue.
However, the presence of b3-adrenergic receptors in
WAT [35] independently of a wide site-related variation
[36], provides an additional foothold for their overall
lipolytic and thermogenic effects; the increased cAMP
levels found in WAT in B3A rats agree with their pre-
sence and functionality in the tissue. Curiously, B3A did
not down-regulate the gene expression of the very
receptors on which it acts, the b3 in contrast with the
known problem of most b3-receptor agonists that
rapidly lose effectiveness because of receptor downregu-
lation [19]. In the present experiment, B3A has acted
continuously (constant injection) for 10 days, inducing a
severe wasting of WAT, but b3-adrenoceptors were
downregulated by OE and not by B3A. This suggests
that the generalized increase in gene expression induced
by B3A is not only a consequence of its effects on its
receptors, but possibly an effect also mediated through
other hormonal or metabolic signal(s) affecting the
whole animal but which effects were patently observed
in WAT.
When the data for cAMP were calculated as nmol/g of
tissue (a rough measure of its actual concentration in
the tissue fluids) and correlated with the loss of weight
experienced by the WAT site, irrespective of the treat-
ment (i.e. controls, OE, B3A and their combination), we
obtained a significant relationship between both para-
meters (r
2 = 0.813; p < 0.0001). There were no differ-
ences between OE and B3A, which suggests that the
loss of tissue weight (i.e. fat) was a closely direct corre-
late of the functional concentration of cAMP in the tis-
sue. The increase in cAMP also elicited a marked
increase in the expression of the phosphodiesterase gene
(about twice than that of combined b receptors). Thus,
fat mobilization was largely induced via cAMP cascade,
and the mechanisms to control this increase were
appropriately set in place both for OE and B3A.
However, the almost universal increase in gene
expression observed in rats treated with B3A suggests
that probably its main effect is not the simple
mobilization of fat, which proceeds at a pace compar-
able to that of OE -in fact carried out with much less
fanfare- since there is a parallel stimulation of both lipo-
lytic and lipogenic paths; glucose entry is probably
enhanced (GLUT4, insulin receptor gene expressions) to
fuel lipogenesis (SREBP1c, acetyl-CoA carboxylase, fatty
acid synthase gene expressions), which combined with
increased lipoprotein lipase and fatty acid transporters
must provide a sizeable entry of substrates from the
plasma. The problem is that lipolysis (hormone-sensitive
lipase, adipocyte triacylglycerol lipase) and cAMP were
also enhanced. All PPAR gene expressions, both lipo-
genic [37] and lipolytic [38] were also increased. Even
contrary signals such as adiponectin and resistin were
probably stimulated. The effectiveness of a contradictory
stimulation of opposed pathways results in itself in a
relative waste of energy, in a Penelope’s Web way.
The limited overall effects of B3A on body size may in
part reflect this disorganized process: adrenergic stimu-
lation usually induces the loss of body weight through
fat mobilization, but b2 agonists have been observed to
increase body weight by modifying the accumulation of
protein in muscle (e.g. clembuterol, [39]), an effect in
part shared by other b3 agonists [40].
T h ec o n s i d e r a b l ei n c r e a s ei nt h ee x p r e s s i o no fU C P 1
gene due to B3A stimulation (56× alone or 68× com-
bined with OE) (Figure 3), yields an amount of UCP1
mRNA in the range of 15 % of that found in the
Figure 3 Combined WAT (i.e. subcutaneous inguinal,
epididymal and retroperitoneal) content of UCP1 gene mRNA
in overweight rats treated with OE and/or B3A for 10 days. The
data are the mean ± sem of six different animals. Statistical
significance of the differences between groups: asterisk = p < 0.05
versus controls; black circle = p < 0.05 OE versus B3A and B3A+OE;
no significant differences were found between B3A and B3A+OE.
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male rat (unpublished data). This may represent that
WAT plays a role in the marked increase of thermogen-
esis elicited by B3A, both in this same experimental
model [15] and others [34]. The “browning” of WAT
was less affected by OE, which, in turn, decreased the
gene expression of UCP2 and UCP3, which function
seems more related with transport and regulation [41]
than pure thermogenesis, reserved to UCP1 [42]. The
increase in UCP1 mRNA content represents an even
higher concentration per unit of tissue weight/per cell,
since the WAT mass shrunk considerably compared
with controls. In spite of OE not changing (or relatively
decreasing) UCP1 gene expression in BAT [43], its more
limited effect on WAT (8× increase) could not be linked
with adrenergic stimulation (low cAMP levels), and
agrees with the marked differences in energy metabo-
lism observed in brown adipose tissue [38] compared
with WAT [44]
There are reports linking the conversion of white to
brown adipocytes as a consequence of continued cate-
cholaminergic stimulation [45]; in the present study,
however, subcutaneous WAT did not respond to these
same stimuli as did the other WAT masses. The analysis
of WAT metabolism and overall function as an organ
[46] or as a cluster of similar organs, is thoroughly com-
plicated by their diversity in substrate processing,
response to hormonal stimuli and their implication in
the regulation of energy homeostasis [47]. A simple look
at Figure 2 shows that subcutaneous WAT responds
more easily to OE and B3A than the retroperitoneal,
and the differences between epididymal and retroperito-
neal (they are in part anatomically connected in the rat
visceral cavity) are also considerable.
It is unclear whether the marked alterations in gene
expression observed here translate into changes of their
corresponding proteins, but at least they are a fair indi-
cator of the processes that are activated, and the loss of
fat (i.e. lower cell size and lower WAT site sizes) is a
proven consequence that adequately fits with this
explanation.
In sum, it is rather surprising that two different agents,
with different mechanisms of action, that elicit widely
opposed responses in WAT gene expression (OE stealthy
but focused in the substrate imbalance; B3A loud and
contrasting, resulting in handling-derived energy waste)
end producing a very similar effect: shrinking of WAT,
loss of fat, maintenance of cell numbers (i.e. practically
no apoptosis). In addition, at the level of the whole ani-
mal, their effects are additive: OE decreases appetite, B3A
increases thermogenesis, both waste WAT: the result is
an accelerated loss of energy of up to 2.5 % of body
energy per day in overweight rats [15].
Conclusions
OE and B3A, elicit widely different responses in WAT
gene expression on the three sites studied. Both drugs
final effects were similar: shrinking of WAT size because
of loss of fat but maintenance of cell numbers. OE acted
essentially on the balance of lipolysis-lipogenesis and the
blocking of the uptake of substrates; essentially hamper-
ing synthesis, and thus favoring lipolysis indirectly. B3A
induced a shotgun increase in the expression of most
regulatory systems in the adipocyte, an effect that in the
end favored again the loss of lipid, probably due to the
loss of metabolic coordination; this barely selective
increase probably produces inefficiency. The waste of
energy induced by B3A was compounded by the
increase in UCP1 gene expression, since UCP1 provides
thermogenic capability to adipocytes, thus increasing the
energy waste by WAT itself as a contribution to the
increase in overall thermogenesis induced by B3A.
Thus, OE in general lowered gene expression and
stealthily induced a substrate imbalance. B3A increasing
the expression of most genes enhanced energy waste
through inefficiency rather than through specific path-
way activation. There was not a synergistic effect
between OE and B3A in WAT, but their combined
action increased WAT energy waste.
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